retatrutide mechanism of action triple hormone receptor agonist (Triple-Action Jab): Phase III trial results published in The Lancet reveal that this triple-hormone (targeting GLP-1, GIP, and glucagon receptors) achieves unprecedented First Retatrutide phase 3 data,
Pay in 4 interest-free payments of $5.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



























